No Data
No Data
Merus Insider Sold Shares Worth $270,000, According to a Recent SEC Filing
CCORF Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $67
Analysts Conflicted on These Healthcare Names: Merus (MRUS), Staar Surgical (STAA) and Rani Therapeutics Holdings (RANI)
Express News | Merus NV : Citigroup Cuts Target Price to $89 From $93
Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates
Analysts Offer Insights on Healthcare Companies: Merus (MRUS), Brookdale Senior Living (BKD) and Arrowhead Pharmaceuticals (ARWR)